AP Healthcare Past Earnings Performance
Past criteria checks 4/6
AP Healthcare has been growing earnings at an average annual rate of 30.7%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 15.2% per year. AP Healthcare's return on equity is 1.5%, and it has net margins of 26.9%.
Key information
30.7%
Earnings growth rate
24.2%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -15.2% |
| Return on equity | 1.5% |
| Net Margin | 26.9% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How AP Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 16,007 | 4,304 | 25,009 | 794 |
| 30 Sep 23 | 14,232 | 14,940 | 5,598 | 605 |
| 30 Jun 23 | 12,810 | 10,967 | 5,600 | 400 |
| 31 Mar 23 | 11,466 | 11,670 | 5,208 | 208 |
| 31 Dec 22 | 9,598 | 2,431 | 6,046 | 0 |
| 30 Sep 22 | 9,003 | 6,706 | 2,900 | 6 |
| 30 Jun 22 | 8,980 | 5,115 | 3,028 | 4 |
| 31 Mar 22 | 8,989 | 3,853 | 3,611 | 0 |
| 31 Dec 21 | 8,416 | 2,650 | 4,020 | 0 |
| 30 Sep 21 | 8,590 | 1,428 | 4,253 | 0 |
| 30 Jun 21 | 8,844 | 6,411 | 2,581 | 0 |
| 31 Mar 21 | 9,064 | 12,068 | 2,447 | 0 |
| 31 Dec 20 | 10,319 | 11,084 | 2,397 | 0 |
| 30 Sep 20 | 12,784 | 8,485 | 2,651 | 0 |
| 30 Jun 20 | 15,308 | 4,259 | 5,100 | 0 |
| 31 Mar 20 | 18,158 | 2,651 | 5,275 | 0 |
| 31 Dec 19 | 21,901 | -6,755 | 6,499 | 0 |
| 30 Sep 19 | 24,284 | -10,959 | 5,783 | 0 |
| 30 Jun 19 | 22,553 | 343 | 5,112 | 0 |
| 31 Mar 19 | 20,728 | -1,711 | 4,788 | 0 |
| 31 Dec 18 | 17,580 | 8,686 | 3,798 | 0 |
| 30 Sep 18 | 14,141 | 11,448 | 6,546 | 0 |
| 30 Jun 18 | 14,604 | -1,124 | 6,987 | 0 |
| 31 Mar 18 | 14,004 | -2,693 | 7,146 | 0 |
| 31 Dec 17 | 11,242 | -3,863 | 6,753 | 0 |
| 30 Sep 17 | 9,119 | -14,590 | 6,962 | 0 |
| 30 Jun 17 | 6,321 | -16,564 | 6,536 | 18 |
| 31 Mar 17 | 5,302 | -18,949 | 7,147 | -1 |
| 31 Dec 16 | 9,821 | -22,411 | 11,198 | 18 |
| 30 Sep 16 | 11,177 | -10,228 | 9,350 | 32 |
| 30 Jun 16 | 12,132 | -9,165 | 9,405 | 38 |
| 31 Dec 15 | 11,117 | -2,556 | 4,836 | 97 |
| 30 Sep 14 | 14,778 | -3,532 | 3,998 | 264 |
| 30 Jun 14 | 16,853 | -4,146 | 4,603 | 264 |
| 31 Mar 14 | 19,771 | -3,639 | 4,592 | 245 |
| 31 Dec 13 | 20,704 | -3,668 | 4,898 | 214 |
| 30 Sep 13 | 19,737 | -857 | 4,601 | 0 |
| 30 Jun 13 | 19,439 | -1,024 | 3,983 | 0 |
Quality Earnings: A109960 has a large one-off gain of ₩32.1B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: A109960's current net profit margins (26.9%) are higher than last year (25.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A109960 has become profitable over the past 5 years, growing earnings by 30.7% per year.
Accelerating Growth: A109960's earnings growth over the past year (77.1%) exceeds its 5-year average (30.7% per year).
Earnings vs Industry: A109960 earnings growth over the past year (77.1%) exceeded the Biotechs industry 28.8%.
Return on Equity
High ROE: A109960's Return on Equity (1.5%) is considered low.